Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer By Ogkologos - April 7, 2026 106 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POLAR study Source RELATED ARTICLESMORE FROM AUTHOR Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in People Without Diabetes EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) MOST POPULAR Approval Expanded for Venetoclax in Chronic Lymphocytic Leukemia June 22, 2018 Ranking of Molecular Alterations in HNSCC According to ESCAT Classification Provides... February 9, 2021 FDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Follicular Lymphoma June 3, 2024 ESMO Immuno-Oncology Congress 2023, 6-8 December 2023, Geneva, Switzerland November 29, 2023 Load more HOT NEWS Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy... EMA Recommends Granting a Marketing Authorisation for Capivasertib The EPA’s Limitations On This Toxic Pesticide Put Children At Risk... Three cancer drugs approved for NHS use in Scotland
